Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

rscheringpharma.de .

Forward-Looking Statements

This press release contains forward-looking statements, including statements about the initiation of clinical trials, regulatory plans and expected timelines for alemtuzumab, including the initiation of a second Phase 3 trial in MS patients and the timing thereof, the timing of obtaining clinical trial data, enrollment in clinical trials and the ability to manage patient safety. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: that final results of the clinical trial demonstrate safety and efficacy comparable to the interim data that have emerged to date, the actual timing and content of submissions to and decisions made by the regulatory authorities, institutional review boards, data safety monitoring boards and treating physicians regarding the continued administration of alemtuzumab to MS patients, Genzyme's ability to develop and obtain approval of a patient safety plan, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements

Genzyme(R), Campath(R), and MabCampath(R) are registered trademarks of Genzyme Corporation. All rights reserved. Rebif(R) is a registered trademark of EMD Serono, Inc.<
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- On Thursday, July 10, 2014, ... Jones Industrial Average finished the day 0.42% lower at 16,915.07, ... losses were broad based as eight out of ten sectors ... Sector Index ended the day at 711.88, down 0.02%, while ... Investor-Edge has initiated coverage on the following equities: Covidien PLC ...
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... Ill., April 11, 2011 Hospira, Inc. (NYSE: ... company, today announced that the company will present at the ... on Wednesday, May 11, 2011, in Las Vegas. ... time on Wednesday, May 11, 2011.  It will be available ...
... PharMEDium Healthcare Corporation has become an Industry Supporter ... part of a new Corporate Supporter program available to ... David N. Jonas, PharMEDium Chairman and CEO commented, "We ... anesthesiology field through leadership, education and research.  As a ...
Cached Medicine Technology:PharMEDium Becomes a Corporate Supporter of the American Society of Anesthesiologists (ASA) 2
(Date:7/13/2014)... The report “Micronutrient Market by Type (Zinc, Manganese, ... Chelated), Application Mode (Soil, Foliar, Fertigation), Crop Type ... 2018” defines and segments the global agriculture micronutrients ... global value and volume for agriculture micronutrients. It ... the global agriculture micronutrients market with an analysis ...
(Date:7/13/2014)... According to a new market research ... Component (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), ... - Forecast and Analysis to 2014-2020", published by ... Market is expected to reach $61.70 Billion by ... 2014 to 2020. , Browse 71 market data ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & ... second bellwether trial, which is expected to get underway ... issued in the U.S. District Court, Southern District of ... will be held on August 7, 2014 at 3:00 ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers ... released its new range of elegant Quinceanera dresses ... at discounted prices. Worldwide clients can enjoy this special ... company’s online shop, there are plenty of beautiful dresses ... great materials. MyDressCity.com’s hot items are prom gowns, bridesmaid ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2
... for bowel cancer based upon a molecule found only in ... curable if caught early. Screening with sigmoidoscopy - an internal ... disease. Now researchers in the find that a reliable test ... ,The bowel sheds cells into feces all the time. The ...
... The West Indian Cherry or Acerola fruit (Malpighia Punicifolia ... to man. Hundred grams of edible portion yields 1000 ... Cherry tree grows well in the tropical parts in ... is rich in Vitamin A, potassium, calcium, phosphorus and ...
... results from a study of a new drug for ... delivered intravenously every three weeks, was found to be ... is one of a group of drugs called chloroethylnitrosoureas. ... been shown to help shrink solid tumors, including cancerous ...
... middle-aged mice which shows that a low-cal diet keeps the ... extending the lifespan// - and this has been found in ... low-cal diet prevents the genetic changes that signal the aging ... used 'gene chip' technology to analyse thousands of genes active ...
... Ireland, Boston and the Netherlands, it was confirmed that ... the air really can save lives. The investigators in Dublin ... coal in Dublin. They studied the death rates in the ... the ban, the amount of black smoke decreased by about ...
... seafood at least once a week have a reduced risk of ... 1205 people aged over 65 //and without dementia at the beginning. ... seafood, then followed them up to, five and seven years afterwards. ... a week had a significantly lower risk of being diagnosed with ...
Cached Medicine News:
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 6.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 12 mm....
Medicine Products: